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Abstract
Background: Laboratory blood testing incurs financial costs and the blood draws can increase discomfort, yet minimal
data exists regarding routine testing in gynecologic oncology surgical patients. Additionally, an increasing number of
gynecologic oncology surgeries are performed via a laparoscopic approach. Thus, further investigation into peri-
operative laboratory testing for gynecologic oncology patients is warranted. An increasing number of gynecologic
oncology surgeries are performed via a laparoscopic approach. Thus, further investigation into perioperative laboratory
testing for gynecologic oncology patients is warranted. Objective: The aims of this study were (1) to evaluate the
frequency and etiology of perioperative laboratory test abnormalities in patients undergoing laparoscopic and lapa-
rotomy surgery in a gynecologic oncology service, and (2) to establish an evidence-based algorithm to reduce unnec-
essary laboratory testing.Materials andMethods:A single-institution retrospective study was completed, investigating
laparoscopic and laparotomic surgeries over 4 years. Information on preoperative and postoperative laboratory data,
surgical parameters, perioperative interventions, and patient demographics was collected. Quality-assurance data were
reviewed. Data were tabulated and analyzed using Statistical Product and Service Solutions (SPSS) version 22. A
Student’s t-testwas used to test for groupdifferences for continuous variableswith equal variance, theMann-Whitney–U
test for continuous variables when unequal variance was detected, and Pearson’s v2 was used to investigate categorical
variables of interest. p-Values <0.05were considered to be statistically significant. Logistic regressionwas performed to
investigate the relationships among multiple predictors and each identified outcome. Results: The study included 481
subjects (168 laparoscopies, 313 laparotomies). Patients undergoing laparoscopywere, on average, younger (53.5 versus
57.4), with lower body mass indexes (29.7 versus 33.0) and lower rates of diabetes (10.7% versus 19.5%), compared to
patients undergoing laparotomy. Overall, >98% of patients underwent at least one preoperative and postoperative
laboratory test, totaling 8060 preoperative and 5784 postoperative results. The laparoscopy group was significantly less
likely to have postoperative metabolic abnormalities or to undergo perioperative blood transfusion. Patients taking an
angiotensin-converting-enzyme inhibitor, angiotensin-II–receptor blocker, or diuretic were significantly more likely to
have elevated creatinine preoperatively (odds ratio [OR]: 5.0; p<0.001) and postoperatively (OR: 7.1; p<0.001), and
this remained true for each group when divided by surgical approach. Perioperative complications meeting institu-
tional quality assurance criteria occurred in 1.7% of laparoscopy patients compared to 11.8% of laparotomy patients
(p<0.001); perioperative laboratory testing was not a factor in the diagnosis of these complications. Conclusions:
Clinically significant laboratory abnormalities are uncommon and are less likely to be found on routine perioperative
testing in gynecologic oncology patients undergoing laparoscopy, compared to patients undergoing laparotomy. This
suggests a role for limiting perioperative laboratory blood testing. (J GYNECOL SURG 32:111)
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Introduction
The rationale and utility of perioperative bloodtesting in the gynecologic oncology patient population
has received minimal evaluation in the literature. Laboratory
blood testing is associated with financial costs and requires
patients to undergo blood draws that can increase discomfort.
Gynecologic oncology is also experiencing a significant shift
in surgical approach, with an increasing number of surgeries
completed by laparoscopic approach and an associated de-
crease in conventional open cases.1 Thus, further investiga-
tion into perioperative laboratory testing in the gynecologic
oncology patient population is warranted.
The objectives of this study were (1) to assess the fre-
quency and clinical significance of perioperative laboratory
testing abnormalities in gynecologic oncology patients un-
dergoing laparoscopic and laparotomic surgery, with the
goal of identifying and eliminating unnecessary testing, and
(2) to establish an evidence-based algorithm to reduce un-
necessary laboratory testing. It was hypothesized that (1)
more laboratory tests are obtained than are necessary for
clinical management, (2) the majority of abnormal labora-
tory results are not clinically significant and do not result in
a change in management, and (3) laboratory result abnor-
malities would be less frequent among patients undergoing
laparoscopy. Using these findings, the current authors pro-
pose an algorithm for streamlining perioperative testing in
gynecologic oncology surgical patients.
Materials and Methods
A retrospective study was performed. Institutional Review
Board Project #HUM00045862 was approved on April 19,
2011. Surgical cases performed by three gynecologic on-
cology attending physicians at the University of Michigan
Medical Center, in Ann Arbor, from March 6, 2006, to
March 6, 2010 were identified. Patients were included if
they underwent laparoscopy or laparotomy. Patients were
excluded if they were admitted prior to the date of their
operation, if bowel obstruction was the indication for sur-
gery, if patients were on total parenteral nutrition prior to
surgery, or if they were pregnant or within 6 weeks post-
partum. For patients with more than one surgery, only the
initial procedure was included. Cases converted from lapa-
roscopy to laparotomy were categorized as laparotomy.
Patient characteristics were documented, including age,
body mass index (BMI), race, and final pathologic diagnosis.
Information on the presence of cardiovascular disease and/or
diabetes mellitus was collected from patient preoperative
history and physical documentation; home medications re-
corded included angiotensin-converting-enzyme (ACE) in-
hibitors, angiotensin-II–receptor blockers (ARB), insulin, oral
hypoglycemics, diuretics, and potassium supplements. Pre-
operativemechanical bowel preparationwas also recorded. All
recordswere searched for preoperative and postoperative day 1
blood laboratory testing results, and these values were re-
corded. Hospital and postoperative visit records were searched
for information on postoperative infections and antibiotic use.
Departmental quality-assurance records were reviewed to
determine the number of cases that met quality-assurance
criteria. Each case was then reviewed to determine if and
how laboratory results factored into the identification and
management of the case. Data were tabulated and analyzed
using Statistical Product and Service Solutions (SPSS),
version 22. Student’s t-test was used to test for group dif-
ferences for continuous variables with equal variance,
Mann-Whitney–U test for continuous variables when un-
equal variance was detected, and Pearson’s v2 was used to
investigate categorical variables of interest. p-Values <0.05
were considered to be statistically significant. Logistic re-
gression was performed to investigate the relationships
among multiple predictors and each identified outcome.
Results
Characteristics of the patient cohort
The study involved 481 patients who met the inclusion cri-
teria, with 168 laparoscopy cases and 313 laparotomy cases.
Patient characteristics are listed in Table 1. There was no sta-
tistically significant difference in surgical approach (laparos-
copy versus laparotomy) for any race. The average BMI for all
patients was 31.8 kg/m2; patients with a BMI >40kg/m2 had 5
times the odds of undergoing surgery via laparotomy, com-
pared to laparoscopy ( p= 0.047). Final pathologic diagnosis
was malignancy in 85.1% of laparoscopies and in 74.1% of
laparotomies, for a total of 78% of the cases.
Cardiovascular disease was reported in 7.3% of the
overall patient population, and no statistical difference was
noted between the laparoscopy and laparotomy cohorts
(Table 1). Approximately 37% of patients reported taking
either an ACE inhibitor/ARB or a diuretic, which were
termed, collectively, as ‘‘renally active medications.’’ A
statistically significant difference according to surgical ap-
proach was observed, with a higher percentage of these
patients undergoing laparotomy ( p = 0.008 for ACE inhibi-
tor/ARB; p = 0.018 for diuretic; Table 1).
Diabetes mellitus was reported in 16.4% of the patients,
including 10.7% of patients undergoing laparoscopy and
19.5% of patients undergoing laparotomy ( p = 0.014; Table
1). Only a subset of diabetic patients was taking insulin
(3.3% of all patients), and these patients underwent lapa-
rotomy more often than laparoscopy ( p = 0.014; Table 1). A
larger percentage of patients (13.1%) were taking oral hy-
poglycemic agents, with no statistically significant differ-
ence in surgical approach.
Surgical parameters were reviewed and compared among
the cohorts (Table 2). Cases performed via laparoscopy were
longer in total operative time (*4 hours versus 3 hours for
laparotomy; p < 0.001). Estimated blood loss (EBL) was
lower for laparoscopy, and blood transfusion occurred in a
total of 59 patients (12.3%), only 1 of whom underwent
laparoscopy ( p < 0.001).
Frequency of laboratory testing and incidence
of abnormalities
The number of patients undergoing laboratory testing is
detailed in Table 3, including preoperative and postopera-
tive comprehensive or basic metabolic panels, magnesium,
phosphate, and complete blood count with platelets. Overall,
>98% of patients underwent at least one preoperative and
postoperative laboratory test, totaling 8060 preoperative and
5784 postoperative individual laboratory results. Of these
results, 11.8% of all preoperative laboratory values were
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outside the normal reporting range and 36.6% of postoper-
ative laboratory results were returned outside the normal
range. The mean number of abnormal laboratory results per
patient was 2.0 (standard deviation [SD]: 2.0) preoperatively
and 4.5 (SD: 2.1) on postoperative day 1. When divided by
cohort, the laparotomy group had a significantly higher
mean number of abnormal laboratory results per patient;
preoperatively 2.4 (SD: 2.1) for laparotomy versus 1.3 (SD
1.4) for laparoscopy, and postoperatively 4.9 (SD: 2.1) for
laparotomy, compared to 3.7 (SD: 1.9) for laparoscopy ( p <
0.001 for both comparisons).
Preoperatively, 412 of the 481 women underwent a
comprehensive metabolic panel (85.7%) and an additional
45 women underwent a basic metabolic panel (9.4%), for a
total of 95.0% of women undergoing some type of preop-
erative metabolic testing. A complete blood count with
platelets was tested in all but 8 women (98.3%).
Laboratory test results were considered to be abnormal if
they fell outside of the University of Michigan laboratory
reference range (Table 3). Despite the high frequency of
preoperative testing, the overall incidence of laboratory
value abnormalities did not exceed 5% for the majority of
the tests. Potentially clinically significant findings are indi-
cated in bold in Table 3. Specifically, 44 patients (9.6%) had
elevated creatinine and 120 patients (26.2%) had elevated
glucose.
Table 1. Patients’ Characteristics According to Surgical Approach
Characteristics All patients (N = 481) Laparoscopy (n= 168) Laparotomy (n = 313) p-Valuea
Age 56.05 (SD: 14.07) 53.46 (SD: 14.63) 57.44 (SD: 13.58) 0.003
BMI 31.83 (SD: 9.69) 29.74 (SD: 6.93) 32.96 (SD: 10.73) <0.001
Race
White or Caucasian 439 (91.3%) 154 (91.7%) 285 (91.1%) 0.867
Black or African American 18 (3.7%) 5 (3.0%) 13 (4.0%) 0.622
Asian 10 (2.1%) 4 (2.4%) 6 (1.9%) 0.743
Native Hawaiian & other
Pacific Islander
2 (0.4%) 0 (0.0%) 2 (0.6%) 0.547
Hispanic 1 (0.2%) 1 (0.6%) 0 (0.0%) 0.345
Other 4 (0.8%) 1 (0.6%) 3 (1.0%) 1.000
Unknown 7 (1.5%) 3 (1.8%) 4 (1.3%) 1.000
Diagnosisb
Endometrial cancer 189 (39.3%) 88 (52.4%) 101 (32.3%) <0.001
Ovarian cancer 111 (23.1%) 14 (8.3%) 97 (31.0%) <0.001
Cervical cancer 56 (11.6%) 37 (22.0%) 19 (6.1%) <0.001
Other malignancy 25 (5.2%) 6 (3.6%) 19 (6.1%) 0.286
Benign 106 (22.0%) 25 (14.9%) 81 (25.9%) 0.006
Comorbidities
Cardiovascular disease 35 (7.3%) 9 (5.4%) 26 (8.3%) 0.273
Diabetes mellitus 79 (16.4%) 18 (10.7%) 61 (19.5%) 0.014
Medications
ACEi/ARB 120 (24.9%) 30 (17.9%) 90 (28.8%) 0.008
Diuretic 113 (23.5%) 29 (17.3%) 84 (26.8%) 0.018
Potassium 17 (3.5%) 3 (1.8%) 14 (4.5%) 0.194
Insulin 16 (3.3%) 1 (0.6%) 15 (4.8%) 0.014
Oral hypoglycemic 63 (13.1%) 17 (10.1%) 46 (14.7%) 0.202
Age and BMI values are listed as mean (SD), all others are n (percentage).
aStatistically significant p-values are indicated in bold.
bPercentages sum to >100%, as 6 patients had diagnoses of synchronous endometrial and ovarian cancers.
BMI, body mass index; SD, standard deviation; ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin-II–receptor blocker.
Table 2. Surgical Data and Blood Transfusions According to Surgical Approach
Factors na All patients Laparoscopy Laparotomy
Surgical time 481 199.9 minutes (SD: 77.7) 238.1 minutes (SD: 71.8) 179.4 minutes (SD: 72.9)
EBL 481 239.5mL (SD: 443.1) 97.2mL (SD: 158.8) 315.9mL (SD: 521.3)
Perioperative transfusionb 481 59 (12.3%) 1 (0.6%) 58 (18.5%)
Intraoperative 481 29 (6.0%) 1 (0.6%) 28 (8.9%)
Postoperative 474 42 (8.9%) 1 (0.6%) 41 (13.4%)
Data are mean (SD), or n (%), or n.
All comparisons of laparotomy to laparoscopy were statistically significant with p < 0.001.
aTotal # of patients for which data were available.
bSome patients underwent both intraoperative and postoperative blood transfusions.
SD, standard deviation; EBL, estimated blood loss.
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Liver function test abnormalities were identified in 62
women with elevated aspartate aminotransferase (AST;
15.0% of tested patients) and 53 women with elevated ala-
nine aminotransferase (ALT; 12.9% of tested patients).
However, only 11 women (2.7%) had either an AST or an
ALT >2 times the upper limit of normal, suggesting that the
incidence of clinically relevant liver function test abnor-
malities is much lower. In addition, of the 95 patients with
the diagnosis of ovarian cancer who underwent preoperative
liver function testing, only 3 women had test results >2
times the upper limit of normal. With regard to preoperative
abnormalities in complete blood count with platelets, 50
women (10.6%) had elevated white blood cell counts and 54
women (11.4%) had elevated platelets. Preoperative anemia
was noted in 107 women (22.6%).
Postoperative laboratory testing abnormalities
by cohort
In the postoperative setting, 356 women had a basic met-
abolic panel test (74.0%) and 27 women had a comprehensive
metabolic panel test (5.6%, Table 3). The incidence of lab-
oratory result abnormalities was higher postoperatively than
preoperatively. Twenty-six women (6.8%) had elevated cre-
atinine, and 318 women (83.0%) had elevated glucose. In
addition, 4.5% of laparoscopy patients and 5.5% of lapa-
rotomy patients had glucose above 200mg/dL (data not
shown). Electrolyte abnormalities were not infrequent in
those patients tested, with hyponatremia in 8.4%, hypo-
magnesemia in 3.6%, and hypophosphatemia in 21.3%.
Aberrations in potassium levels were relatively uncommon
on postoperative day 1, with 4.4% and 1.6% of tested
patients being hyperkalemic and hypokalemic, respec-
tively. The laparoscopy group was significantly less likely
to have hyponatremia, elevated creatinine or urea nitrogen,
and hypomagnesemia on postoperative day 1 (Table 4).
Despite the number of electrolyte abnormalities seen,
changes were most often mild and triggered interven-
tions such as changing intravenous fluid or electrolyte
supplementation.
Almost all women (472, 98.1%) had a postoperative
complete blood count with platelets tested. Hemoglobin
level was below the institutional normal of 12.0 g/dL in
355 women (75.2%); postoperative anemia was signifi-
cantly less likely in the laparoscopy group (67.7% versus
79.1%; odds ratio [OR]: 0.14; p = 0.009). The more strin-
gent criterion of hemoglobin <7 g/dL was then considered,
given the guidelines recommending that transfusion be
considered for patients whose hemoglobin fell below this
threshold.2 Only 1 patient met this criterion, and she un-
derwent a laparoscopy. This patient had a preoperative
hemoglobin level of 7.3 g/dL and a postoperative hemo-
globin level of 6.2 g/dL; however, she did not receive a
perioperative blood transfusion.
Elevated white blood cell counts were noted in 223 women
(47.2%). Infections were documented in 86 women (17.9%),
Table 3. Perioperative Laboratory Results for All Patients
Preoperative testing Postoperative day 1 testing
Test Normal rangea nb (%)
High
values (%)
Low
values (%) nb (%)
High
values (%)
Low
values (%)
Sodium 136–146mmol/L 457 (95.0%) 0 22 (4.6%) 383 (79.6%) 3 (0.8%) 32 (8.4%)
Potassium 3.5–5.0mmol/L 457 (95.0%) 18 (3.9%) 11 (2.4%) 383 (79.6%) 17 (4.4%) 6 (1.6%)
Chloride 98–108mmol/L 457 (95.0%) 28 (6.1%) 12 (2.6%) 383 (79.6%) 89 (23.2%) 4 (1.0%)
CO2 22–34mmol/L 457 (95.0%) 5 (1.1%) 9 (2.0%) 383 (79.6%) 2 (0.5%) 11 (2.9%)
UN 8–20mg/dL 457 (95.0%) 67 (14.7%) 11 (2.4%) 383 (79.6%) 23 (6.0%) 101 (26.4%)
Creatinine 0.5–1.0mg/dL 458 (95.2%) 44 (9.6%) 4 (0.9%) 383 (79.6%) 26 (6.8%) 22 (5.7%)
Glucose 73–110mg/dL 458 (95.2%) 120 (26.2%) 9 (2.0%) 383 (79.6%) 318 (83.0%) 1 (0.3%)
Calcium 8.6–10.3mg/dL 457 (95.0%) 15 (3.3%) 8 (1.8%) 383 (79.6%) 1 (0.3%) 264 (68.9%)
Protein 6.0–8.3 g/dL 412 (85.7%) 1 (0.2%) 9 (2.2%) 27 (5.5%) 0 20 (74.1%)
Albumin 3.5–4.9 g/dL 414 (86.1%) 5 (1.2%) 10 (2.4%) 28 (5.7%) 0 18 (64.3%)
AST 8–30 IU/L 412 (85.7%) 62 (15.0%) 1 (0.2%) 27 (5.5%) 8 (29.6%) 2 (7.4%)
ALT 7–35 IU/L 412 (85.7%) 53 (12.9%) 7 (1.7%) 27 (5.5%) 5 (18.5%) 2 (7.4%)
Alk
Phosphatase
30–130 IU/L 412 (85.7%) 28 (6.8%) 1 (0.2%) 27 (5.5%) 2 (7.4%) 2 (7.4%)
Total bilirubin 0.2–1.2mg/dL 412 (85.7%) 6 (1.5%) 2 (0.5%) 27 (5.5%) 2 (7.4%) 0
Magnesium 2.7–4.6mg/dL 19 (4.0%) 1 (5.3%) 0 342 (69.8%) 8 (2.4%) 12 (3.6%)
Phosphate 1.5–2.4mg/dL 18 (3.7%) 1 (5.6%) 2 (11.1%) 340 (69.4%) 13 (3.9%) 71 (21.3%)
White blood
cells
4.0–10.0K/mm3 473 (98.3%) 50 (10.6%) 17 (3.6%) 472 (98.1%) 223 (47.2%) 2 (0.4%)
Hemoglobin 12.0–16.0 g/dL 473 (98.3%) 3 (0.6%) 107 (22.6%) 472 (98.1%) 1 (0.2%) 355 (75.2%)
Hematocrit 36.0%–48.0% 473 (98.3%) 0 133 (28.1%) 472 (98.1%) 1 (0.2%) 394 (83.5%)
Platelets 150–400K/mm3 472 (98.1%) 54 (11.4%) 16 (3.4%) 471 (97.9%) 21 (4.5%) 34 (7.2%)
Data are n (%), or n.
Potentially clinically significant findings are indicated in bold.
aNormal range per University of Michigan, Ann Arbor, laboratory.
bNumber of patients undergoing each test.
CO2, carbon dioxide; UN, urea nitrogen; AST, aspartate aminotransferase; IU, international units; ALT, alanine aminotransferase; Alk,
alkaline.
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with the majority of these in the laparotomy group (laparotomy
75, laparoscopy 11; OR: 22.58; p<0.001). Of these infections,
62% were of the urinary tract and 13% were of wounds.
Women with elevated white blood cell counts had more than
twice the odds of receiving postoperative antibiotics (OR: 2.21;
95% confidence interval [CI]: 1.43–3.42; p<0.001), and were
at higher odds of having a documented postoperative infection
(OR: 1.61; 95% CI: 1.01–2.59; p=0.047) when analyzed by
logistic regression.
Given the frequency of creatinine abnormalities in the
perioperative period and potential implications for perio-
perative management, including fluid management and the
dosing of renally cleared medications, the patients with
creatinine abnormalities were examined further. Forty-four
of 458 (9.6%) women had creatinine levels >1.0 preopera-
tively; postoperatively, 26 of 390 (6.8%) women had cre-
atinine levels >1.0. Multiple logistic regressions were
performed to determine predictors of patients with elevated
serum creatinine (Table 5). Diabetes and all renally active
medications were statistically significant predictors of ele-
vated creatinine levels in both preoperative and postopera-
tive laboratory testing.
Role of laboratory abnormalities in identifying
perioperative complications
Finally, departmental quality-assurance records were
examined to determine the number of patients meeting
criteria for perioperative complication and if perioperative
laboratory testing was a factor in identifying complica-
tions. Overall, 40/481 (8.3%) of patients met institutional
quality-assurance criteria. This included 3 laparoscopy
cases (1.8%) and 37 laparotomy cases (11.9%; OR: 14.4;
p < 0.001). Individual chart reviews revealed that none of
the complications in these cases were initially diagnosed
because of abnormalities in routine postoperative labora-
tory test results.
Discussion
The vast majority of patients undergoing surgery in the
gynecologic oncology service at the University of Michigan
had perioperative laboratory blood testing. Despite the high
frequency of testing, few clinically relevant abnormal test
results were obtained.
Given the above findings, the current authors propose the
following guidelines for limiting perioperative laboratory
testing. The current authors recommend that all patients
undergo preoperative complete blood count testing for
anemia and basic metabolic testing to capture both glucose
and creatinine abnormalities. Postoperatively, the current
authors propose no routine testing for laparoscopy patients.
For laparotomy patients, given the higher rates of anemia
and glucose abnormalities that were noted, the current au-
thors recommend complete blood count testing and glucose
assessment. All patients on a renally active medication
should also undergo postoperative creatinine testing.
Departmental quality-assurance records were reviewed to
determine if adopting the above guidelines would potentially
have affected patient outcomes adversely. In reviewing the
details of each specific case, it was determined that none of
the cases would have had a delayed diagnosis or a worsened
outcome by following the proposed recommendations.
Anemia was common preoperatively, and thus likely
warrants obtaining a preoperative complete blood count with
platelets to allow blood-product planning by the surgical and
anesthesia teams. In patients undergoing laparotomy, the
current authors were unable to identify an EBL threshold that
could be used to define the subset of patients undergoing
laparotomy in whom to check postoperative hemoglobin
levels (data not shown). Obtaining postoperative hemoglobin
levels in patients undergoing laparoscopy can be limited to
those in whom there is clinical suspicion of anemia.
Electrolyte abnormalities were relatively uncommon
postoperatively and often triggered interventions, such as
changes to intravenous fluids and electrolyte replacement,
that likely had little impact on postoperative recovery. In
addition, electrolyte replacements are costly, particularly
when administered intravenously. In contrast, glucose ab-
normalities were common, and 5.2% of patients had blood
glucose values >200mg/dL. Given the important role of
glycemic control in postoperative healing,3 continued point-
of-care blood glucose value monitoring is prudent in pa-
tients who are diabetic or whom undergo laparotomy and
have elevated blood glucose levels postoperatively.
The implementation of new perioperative blood testing
guidelines has the potential to improve many aspects of care,
including decreasing perioperative laboratory fees and min-
imizing patient discomfort. Significant additional savings
would be incurred, including eliminating unnecessary follow-
up laboratory tests, phlebotomy fees, and electrolyte sup-
plementation costs. In addition to gynecologic oncology pa-
tients, these findings are also applicable to themanagement of
patients undergoing surgical intervention for benign gyne-
cologic disease.
Table 5. Logistic Regression Analysis of Factors Influencing Perioperative Serum Creatinine Level
Result na Patient factor OR 95% CI p-Value
Preoperative Cr >1 458 Diabetes 2.42 1.37–4.29 0.002
ACEi/ARB medication 3.98 2.38–6.65 <0.001
Diuretic medication 4.31 2.57–7.23 <0.001
Postoperative Cr >1 383 Diabetes 3.43 1.69–6.97 0.001
ACEi/ARB medication 4.59 2.32–9.11 <0.001
Diuretic medication 4.18 2.12–8.26 <0.001
aNumber of patients undergoing each test.
OR, odds ratio; CI, confidence interval; Cr, serum creatinine; ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin-II–
receptor blocker.
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While there are guidelines for preoperative testing, such
as the National Institute of Clinical Excellence perioperative
guidelines,4 a recent study in the benign gynecology patient
population demonstrated that, in these surgical patients, the
guidelines are rarely followed, with 90% of women under-
going at least one nonindicated test.5 A number of studies
have examined the incidence of preoperative laboratory
abnormalities in surgical patients other than the gynecology
population. In one such study, the incidence of preoperative
laboratory abnormalities was low and was not predictive of
adverse outcomes in the postoperative period.6
Findings such as these have led to more streamlined
testing for elective surgical procedures. One institution
eliminated preoperative laboratory screening tests for heal-
thy patients undergoing elective surgical procedures.7 In-
vestigators found that patients without specific indications
for testing can undergo surgery safely without preoperative
laboratory tests.8 Another study examining elective surgery
patients revealed that only 0.22% of the routine preoperative
tests ordered revealed abnormalities that might influence
perioperative management.9 These abnormalities did not
result in adverse surgical or anesthetic outcomes. In addi-
tion, not only has research demonstrated that routine pre-
operative testing is often unnecessary based on the low
incidence of abnormal test results, it also increases cost.10
One study examining the impact of new guidelines to de-
crease testing in the ambulatory surgery setting demon-
strated that new hospital guidelines were effective for
reducing preoperative testing without increasing untoward
perioperative events.11
Many studies have analyzed the cost-effectiveness of
preoperative type and screen testing in patients undergoing
elective gynecologic surgery for benign indications, and
demonstrated that such testing is not cost-effective.12,13
However, <2.5% of the studied patients required transfusion
in the perioperative period. Given the higher transfusion rate
of 12% in gynecologic oncology patients undergoing lapa-
rotomy, and the possibility of conversion from laparoscopy
to laparotomy intraoperatively, the current authors believe
that preoperative type and screen testing should be obtained
in all gynecologic oncology patients.
In the postoperative period, available guidance is more
limited. Studies have demonstrated that only a small fraction
of abnormal laboratory values actually trigger interventions
by providers. In a study of women undergoing elective
gynecologic surgery, the overall incidence of blood trans-
fusion was 1.9%, with none of these transfusions triggered
specifically based on the postoperative hematocrit value.14
A more recent study of women undergoing total laparo-
scopic hysterectomy found routine postoperative hemoglo-
bin testing to be of little clinical benefit in the absence of
clinical signs and symptoms of anemia and that results did
not guide clinical care.15
Despite the above body of research investigating preop-
erative and postoperative blood test frequency and incidence
of abnormalities, to the current authors’ knowledge no
studies have been performed in patients on a gynecologic
oncology service. These patients represent a unique popu-
lation. From a demographic standpoint, they are women of
varying ages and with a spectrum of comorbidities, both in
number and type. The most similar study with regard to
patient population is one that examined routine postopera-
tive laboratory studies in 105 patients with colorectal cancer
undergoing surgical resection. The investigators found that,
although minor laboratory abnormalities were common
postoperatively (12%–67% depending on the test), only a
very small subset (0.03%–5.1% depending on the test)
triggered an intervention.16 Overall, those authors reported
that serum potassium, hemoglobin, and serum glucose in
patients with diabetes were the only values that led to
therapeutic decisions.16
Limitations of the current study include its retrospective na-
ture and the patient population represented. More than 90% of
the women were Caucasian, and the average BMI was 31.8.
In addition, variations in practice patterns regarding surgical
aggressiveness intraoperatively for debulking and intraoperative
anesthesia practices may influence the development and man-
agement of postoperative electrolyte abnormalities.
Conclusions
Future directions can include prospective cost and quality-
assurance monitoring with the proposed reduction in perio-
perative tests to validate the safety of a reduced testing strategy.
Clinically significant laboratory abnormalities are uncommon
and are less likely to be found on routine perioperative testing
in gynecologic oncology patients undergoing laparoscopy as
compared to patients undergoing laparotomy. This suggests a
role for limiting perioperative laboratory blood testing.
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